SYDNEY, Australia, May 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces participation at upcoming industry conferences.
| Conference: | New York Academy of Sciences, Frontiers in Immunotherapy |
| Dates: | May 14-15, 2019 |
| Venue: | The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York, USA |
| Participation: | Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion titled “Novel Approaches from Biotech” |
| Conference: | World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 |
| Dates: | May 15-17, 2019 |
| Venue: | Business Design Centre, London, UK |
| Presentation Title: | Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials |
| Presenter: | Frédéric Triebel, CSO & CMO of Immutep |
| Conference: | American Society for Clinical Oncology (ASCO) Annual Meeting |
| Dates: | May 31 – June 4, 2019 |
| Venue: | McCormick Place, Chicago, IL, USA |
Abstract Number and Title: TPS2667, “A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).”
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Session Data and Time: Saturday, Jun 1, 8:00 - 11:00 a.m. CDT
Location: Hall A, Poster Board Number: #299b
Abstract Number and Title: TPS2651, “The “INSIGHT” Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.”
Poster Session: Developmental Immunotherapy and Tumor Immunobiology
Session Data and Time: Saturday, Jun 1, 8:00 - 11:00 a.m. CDT
Location: Hall A, Poster Board Number: #291b
About Immutep
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Further information can be found on the Company’s website www.immutep.com or by contacting:
U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com